

 **nemluvio**[™]
(nemolizumab-ilt) for injection
30 mg



FDA APPROVED FOR PRURIGO NODULARIS (PN)¹

Itch relief like that

As soon as 48 hours*,
NEMLUVIO[®] relieves itch
fast with skin healing that
lasts—so you can have
better days and nights^{1,2†}

Not an actual patient.

*Data from post-hoc descriptive analysis of daily Peak Pruritus Numerical Rating Scale (PP-NRS) improvement. About half of adults using NEMLUVIO achieved significant itch relief by Week 16 (49% vs 16% with placebo).^{1,2}

†As demonstrated by improvements in quality of life measurements including the Sleep Disturbance Numerical Rating Scale (SD-NRS) for 52% of adults using NEMLUVIO vs 21% using placebo in a clinical trial.²

Important Safety Information

Indication: NEMLUVIO[®] (nemolizumab-ilt) is a prescription medicine used to treat adults with prurigo nodularis.

Please see Important Safety Information throughout, accompanying full Prescribing Information including Patient Information, or visit nemluvio.com.

Do you need fast and lasting itch relief for prurigo nodularis (PN)?

Talk to a dermatologist if you've experienced^{3,4}:


- Intense and/or persistent itch
- Itchy raised nodules (bumps) that may bleed and heal slowly
- Patches of dry and inflamed skin
- Inability to sleep or focus due to intense itch



Not an actual patient.

Let's talk itch *impact*...

It's not just about itch intensity—it's also about how itch can persist and affect so many parts of your life. It can become relentless, impacting your work, relationships, social activities, self-esteem, and sleep. Use this discussion guide to help explain the full impact of itch and foster a more informed conversation with your dermatologist.^{3,4}



DOWNLOAD THE GUIDE
by scanning this code

Ask a dermatologist about NEMLUVIO
for results you can see and feel

Please see accompanying full Prescribing Information, including Patient Information or visit nemludio.com.



Get the relief you've been waiting for with NEMLUVIO



Fast itch relief—as soon as 48 hours^{2*}



Itch relief that lasts so skin can heal²



Long-lasting skin clearance²



Fewer sleepless nights^{2†}



Favorable safety profile¹



~Once-monthly dosing from the start¹

*Data from post-hoc descriptive analysis of daily PP-NRS improvement. About half of adults using NEMLUVIO achieved significant itch relief by Week 16 (49% vs 16% with placebo).^{1,2}

†Adults with PN reported sleeping better while on treatment with NEMLUVIO.²

PP-NRS=Peak Pruritus Numerical Rating Scale.

Important Safety Information

Do not take NEMLUVIO if you are allergic to nemolizumab-ilto or to any ingredients in NEMLUVIO.

Before taking NEMLUVIO, tell your healthcare provider about all of your medical conditions, including if you:


- are scheduled to receive any vaccination. You should not receive a live vaccine right before or during treatment with NEMLUVIO.
- are pregnant or plan to become pregnant. It is not known whether NEMLUVIO will harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known whether NEMLUVIO passes into your breast milk and if it can harm your baby.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Understanding prurigo nodularis (PN)

PN is a chronic skin disease that causes an intense itch from inside the body. The relentless itch can make it almost impossible to stop scratching. PN can lead to itchy raised bumps on the skin called nodules and causes a vicious cycle of itch, inflammation, and discomfort.^{3,5}


PN starts with signals beneath the skin



How NEMLUVIO works

NEMLUVIO is the first and only treatment that blocks IL-31 signaling, a key driver of itch, inflammation, and the formation of PN nodules. By relieving itch and reducing the urge to scratch, NEMLUVIO allows your skin to heal and clear.¹

NEMLUVIO is designed to directly block IL-31 signaling




IL-31=Interleukin-31.

Please see accompanying full Prescribing Information, including Patient Information or visit nemluvio.com.



Fast and lasting itch relief

NEMLUVIO
quickly relieves
the urge to scratch



as soon as
48 hours^{2*}

Itch-free or nearly itch-free

7 OUT OF 10

adults were itch-free or nearly
itch-free[†] over 1 year²

Significant itch relief

8 OUT OF 10

adults achieved and maintained
significant itch relief[‡] over 1 year²

About half of adults using NEMLUVIO had significant itch relief by Week 16
(49% vs 16% with placebo).¹

NEMLUVIO was studied in the largest clinical trial of PN to date⁷

- Over 550 adult participants with moderate-to-severe prurigo nodularis (PN)¹
- Studies evaluated measurements of itch, skin clearance, and effect on sleep, among other factors¹

NEMLUVIO was evaluated in 2 phase 3 clinical trials and a long-term study. Results shown are from the second clinical trial[§] and the long-term study.²

*Data from post-hoc descriptive analysis of daily PP-NRS improvement.²

[†]Itch-free or nearly itch-free was defined as less than 2 on the PP-NRS, where 0 was no itch and 10 was worst itch imaginable.²

[‡]Significant itch relief was defined as an itch improvement of at least 4 points on the PP-NRS.¹

[§]This clinical trial was called OLYMPIA 2.²

^{||}Clear or almost clear skin was defined as a 1 or below on the Investigator's Global Assessment (IGA) scale, where 0 was clear and 4 was severe, with a 2-point improvement from baseline.¹

PP-NRS=Peak Pruritus Numerical Rating Scale.

Please see accompanying full Prescribing
Information, including Patient Information
or visit nemluvio.com.



Skin clearance that lasts

BEFORE
TREATMENT



AFTER
TREATMENT



More than half
of adults in the
clinical trials
had PN nodules
healed at
Week 16²

AFTER
1 YEAR WITH TREATMENT

75%+
clearer skin

Most adults in the
clinical trials had the
majority of PN nodules
healed after 1 year²

31-year-old female. Actual patient from clinical trial. Photo altered to remove identifying marks.

More than one-third of adults in clinical trials achieved clear or almost clear skin^{||} at Week 16 (38% vs 11% with placebo).^{1,2}

Better days and nights ahead



NEMLUVIO helped most adults improve sleep and quality of life, as measured across factors such as the effect of PN on work, life, or social activities.²

Favorable safety profile

The most common side effect for adults using NEMLUVIO was headache (only 6% vs 3% with placebo). Atopic dermatitis and eczema were also seen in more than 1% of adults using NEMLUVIO and more common than placebo.¹

Important Safety Information

NEMLUVIO may cause serious side effects, including: allergic reactions (hypersensitivity).

Stop using NEMLUVIO and tell your healthcare provider or get emergency help right away if you get any of the following symptoms: Breathing problems or wheezing; swelling of the face, lips, mouth, tongue, or throat; fainting, dizziness, feeling lightheaded; fast pulse; swollen lymph nodes; joint pain; fever; skin rash (red or rough skin); nausea or vomiting; general ill feeling; or cramps in your stomach area.

The most common side effects of NEMLUVIO include: Headache, Skin rashes: atopic dermatitis (a type of eczema), eczema, and eczema nummular (scattered circular patches).

These are not all of the possible side effects of NEMLUVIO.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

~Once-monthly dosing from the start

NEMLUVIO is the first and only self-injectable treatment for prurigo nodularis (PN) that you can take approximately once a month.^{1,8}



LEARN HOW TO SELF-INJECT
Scan the code for detailed instructions on how to use NEMLUVIO



Uniquely designed with you in mind



NEMLUVIO is a subcutaneous (under the skin) injection with a convenient prefilled self-injector pen you can use at home. The pen contains **4x less volume** than the other biologic for PN to help ease any potential discomfort.^{1,8,10*}



NEMLUVIO is not a steroid, cream, or immunosuppressant and requires no preliminary lab evaluations or ongoing lab monitoring during treatment.¹



The recommended dose for adults is:

- **One 30-mg injection** every 4 weeks after the initial dose (two 30-mg injections)¹
- **Two 30-mg injections** every 4 weeks for adults weighing more than 198 lb (90 kg)¹



NEMLUVIO may be stored at room temperature up to 77 °F (25 °C) for up to 90 days, making it **easy to take on the go**. Be sure to mark the date after NEMLUVIO is removed from the refrigerator. NEMLUVIO may be stored in the refrigerator at 36 °F to 46 °F until the expiration date.¹



Review the NEMLUVIO Instructions for Use with a dermatologist before you start injections or **talk to a Nurse Navigator** for additional support.

*Provides 30 mg of NEMLUVIO in 0.49 mL of solution vs 2 mL with the other biologic for PN.^{1,8}

Please see accompanying full Prescribing Information, including Patient Information or visit nemluvio.com.



Key questions to ask a dermatologist

1 | Is NEMLUVIO right for me?

2 | How does NEMLUVIO block signals for itch in PN?

3 | How is itch relief with NEMLUVIO different than other treatments I've tried?

4 | When can I expect to see results with NEMLUVIO?

5 | What are the potential side effects of NEMLUVIO?

Important Safety Information

Do not take NEMLUVIO if you are allergic to nemolizumab-ilto or to any ingredients in NEMLUVIO.

Before taking NEMLUVIO, tell your healthcare provider about all of your medical conditions, including if you:

- are scheduled to receive any vaccination. You should not receive a live vaccine right before or during treatment with NEMLUVIO.
- are pregnant or plan to become pregnant. It is not known whether NEMLUVIO will harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known whether NEMLUVIO passes into your breast milk and if it can harm your baby.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Let's navigate NEMLUVIO together

We're here for you from day 1. Your GPS (Galderma Patient Services) for NEMLUVIO™ support team will help you understand insurance benefits and financial assistance, provide one-on-one education, and help you stay on track, including refill reminders.



Financial support and insurance assistance

Talk to your dermatologist or the GPS for NEMLUVIO support team to see whether you are eligible for financial support. You may be able to access a **\$0 co-pay**, receive complementary doses during insurance transitions or delays via **Bridge**, or gain access to NEMLUVIO if your insurance is unable to cover treatment with the **Patient Assistance Program**.*



Nurse Navigator support

A Nurse Navigator will be available to help you manage your treatment successfully by providing:

- **Support for starting NEMLUVIO**, including virtual, in-person, or over-the-phone injection training
- **Answers to any questions** you have about treatment
- **Quarterly check-ins** upon request to track your progress

*See eligibility requirements and terms of use.

Actor portrayal.




Start your enrollment today

Enrolling with GPS for NEMLUVIO is easy. Complete your enrollment online and we'll be in touch to connect you with the support you need.



ENROLL WITH GPS FOR NEMLUVIO online by scanning the code

If you prefer to enroll over the phone, call 1-855-NEMLUVIO, 8:00 AM - 8:00 PM ET, Monday - Friday.



Not an actual patient.

References: 1. NEMLUVIO (nemolizumab-ilto) injection 30 mg Prescribing Information. Dallas, TX: Galderma Laboratories, L.P.; August 2024. 2. Galderma Laboratories, L.P.; data on file. 3. Ludman P. Prurigo nodularis. American Academy of Dermatology Association. Updated September 14, 2021. Accessed June 8, 2024. <https://www.aad.org/public/diseases/a-z/prurigo-nodularis-overview> 4. Rodriguez D, Kwatra SG, Dias-Barbosa C, et al. Patient perspectives on living with severe prurigo nodularis. *JAMA Dermatol.* 2023;159(11):1205-1212. doi:10.1001/jamadermatol.2023.3251 5. Williams KA, Roh YS, Brown I, et al. Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis. *Expert Rev Clin Pharmacol.* 2021;14(1):67-77. doi:10.1080/17512433.2021.1852080

References (continued): 6. Mullins TB, Sharma P, Riley C, et al. Prurigo nodularis. In: *StatPearls*; Treasure Island (FL): StatPearls Publishing; March 1, 2024. 7. Galderma phase III data published in The New England Journal of Medicine: full Olympia 2 trial results demonstrate nemolizumab's rapid onset of action in patients with prurigo nodularis. Galderma Laboratories, L.P. Press release. Published October 26, 2023. Accessed April 18, 2024. 8. DUPIXENT. Prescribing information. Sanofi Genzyme; 2024. 9. Kwatra SG, Yosipovitch G, Legat FJ, et al. Phase 3 trial of nemolizumab in patients with prurigo nodularis. *N Engl J Med.* 2023;389(17):1579-1589. doi:10.1056/NEJMoa2301333 10. Zijlstra E, Jahnke J, Fischer A, et al. Impact of injection speed, volume, and site on pain sensation. *J Diabetes Sci Technol.* 2018;12(1):163-168. doi:10.1177/1932296817735121

Your next steps for itch relief fast with skin healing that lasts^{1,2}

1 | Ask your dermatologist if NEMLUVIO
could be right for you

2 | Get started with GPS for NEMLUVIO today

Learn more about support from GPS (Galderma Patient Services)
for NEMLUVIO and how to complete enrollment at nemluvio.com.

For more information, you can call 1-855-NEMLUVIO,
8:00 AM - 8:00 PM ET, Monday - Friday.

3 | Sign up to stay connected

Receive ongoing education, guidance, and resources to help
along your treatment experience with NEMLUVIO.



SCAN TO SIGN UP

Important Safety Information

Indication: NEMLUVIO® (nemolizumab-ilto) is a prescription medicine used to treat adults
with prurigo nodularis.

**Please see accompanying full Prescribing Information, including Patient Information
or visit nemluvio.com.**

GALDERMA

EST. 1981

©2024 Galderma Laboratories, L.P. All Rights Reserved.
NEMLUVIO is a registered trademark of Galderma.

US-NPN-2400016 08/24



FOLLOW US ON SOCIAL



@nemluvio_nemolizumab



@NEMLUVIO